Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial updating safety, tolerability, pharmacokinetics, and efficacy of AMG 397 in relapsed or refractory hematological malignancies; study status termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• AMG 397

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma, Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2023-04-12